ViewRay, Inc. (VRAY)

WASHINGTON--(BUSINESS WIRE)--In light of ViewRay Systems recent announcement that it would close its doors on October 25, 2023, Dr. Suthanthiran, President/Founder of TeamBest Global Companies (TBG) and Best Cure Foundation, is encouraging all to share their thoughts as to how to preserve, upgrade, innovate, and reduce the cost of technology, service, etc., of ViewRay Systems products—for now and in the future. Suthanthiran has already received numerous inquiries from customers, vendors, and se.

WASHINGTON--(BUSINESS WIRE)--Since the announcement regarding the closing of ViewRay on October 25, 2023, competitors have raced to decommission the ViewRay Systems, replacing them with their own products by establishing relationships with companies that service/decommission/sell refurbished or used equipment—making time of the essence to preserve this valuable technology. While competitors may be motivated to remove ViewRay's systems and offer alternatives, there's a real possibility that the.

WASHINGTON--(BUSINESS WIRE)--Krishnan Suthanthiran offers a solution for continued support and service to ViewRay customers.

DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market.

ViewRay (NASDAQ: VRAY ) stock is falling hard on Monday after the MRI company announced its voluntary Chapter 11 bankruptcy filing! According to the company's bankruptcy filing, ViewRay intends to pursue the sale of its business as part of the Chapter 11 process.

Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER , July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 process.

First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER , June 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER , May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.

ViewRay (VRAY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.

DENVER , May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.

Magnetic resonance imaging-guided radiation therapy system provider ViewRay, Inc. has shocked investors with a severe revenue and cash flow warning. Expected 2023 revenue growth range slashed from a range of 25% to 40% to a new range of 0% to 15%.

DENVER , April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The preliminary results have not been audited and are subject to change.

DENVER , April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786.

Penny stocks with unusual options activity. The post Penny Stocks To Buy Now?

FORT MYERS, Fla.--(BUSINESS WIRE)--GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay's advanced MRIdian MRI-guided radiation therapy system at the Lee Health Regional Cancer Center on Monday, March 27, at its Fort Myers, FL location.